Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report

J Pediatr. 2003 Nov;143(5):674-7. doi: 10.1067/S0022-3476(03)00300-7.

Abstract

We report the successful use of anti-CD20 therapy in a child with refractory myasthenia gravis (MG), an antibody-mediated autoimmune disease, who did not respond to conventional therapy. After initiation of anti-CD20 therapy, clinical improvement (muscular strength, pulmonary function) was observed.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / therapeutic use*
  • Child
  • Female
  • Humans
  • Myasthenia Gravis / drug therapy*
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Rituximab